Evidence map›Paper›PMID 41070194›Full record

ArticleLife metabolism2025

A reductive uric acid degradation pathway in anaerobic bacteria.

Zhi Li, Wei Meng, Zihan Gao, Wanli Peng, Zhandong Hu, Jianhao Zhang, Yining Wang, Xiaoxia Wu, Zipeng Zhao, Chuyuan Zhang and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Urate metabolism in the gut.Life metabolism · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Zhi LiNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Wei MengNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Zihan GaoSchool of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Wanli PengSchool of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Zhandong HuTianjin First Central Hospital, Tianjin 300190, China.
Jianhao ZhangSchool of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Yining WangNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Xiaoxia WuNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Zipeng ZhaoNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Chuyuan ZhangNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Zhuohao TangSchool of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Zhujun NieNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Shaohua WuTianjin First Central Hospital, Tianjin 300190, China.
Benjuan WuTianjin First Central Hospital, Tianjin 300190, China.
Hui ZhengDepartment of Anesthesiology, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Duqiang LuoCollege of Life Sciences, Institute of Life Science and Green Development and Hebei Innovation Center for Bioengineering and Biotechnology, Hebei University, Baoding, Hebei 071002, China.
Yang TongNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Yiling HuNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
Zehan HuSchool of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China.
Yifeng WeiSingapore Institute of Food and Biotechnology Innovation (SIFBI), Agency for Science, Technology and Research (A*STAR), Singapore 138669, Singapore.
Yan ZhangNew Cornerstone Science Laboratory, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uric acid (UA) is a key intermediate in purine degradation across diverse organisms, while its accumulation in humans leads to inflammation and gout disease. Aerobic organisms degrade UA via a well-known "oxidative pathway" involving dearomatization of the purine core catalyzed by UA oxidases or dehydrogenases. The ability to degrade UA is also widespread in anaerobic bacteria, including gut bacteria, although the mechanisms are incompletely understood. Here, we report the biochemical characterization of a recently identified UA degradation gene cluster from

Indexed as

CBT2.0gouturic acidyanthine

Identifiers

PMID41070194
PMCPMC12507026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.